Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord

[Display omitted] Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), A...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmacological research Ročník 143; s. 86 - 96
Hlavní autori:	Kumar, Manish, Kulshrestha, Ritu, Singh, Nirmal, Jaggi, Amteshwar Singh
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Netherlands Elsevier Ltd 01.05.2019
Predmet:	Alzheimer’s disease Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Brain Humans Imatinib Imatinib Mesylate - pharmacology Imatinib Mesylate - therapeutic use Multiple sclerosis Nervous System Diseases - drug therapy Nervous System Diseases - metabolism Parkinson disease Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Spinal Cord Spinal cord injury Stroke Tyrosine kinase NF-κβ Multiple sclerosis BBB FLT3 Parkinson disease Spinal cord injury LPS Aβ Tyrosine kinase AICD PDGFR t-PA Imatinib Stroke AD MOG Alzheimer’s disease c-kit EAE c-Abl MAPK IL-6 MMP β-CTF APC TNF-α Lck ARG AβPP GSAP MPTP HEK cells
ISSN:	1043-6618, 1096-1186, 1096-1186
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	[Display omitted] Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), Abelson related gene (ARG), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), lymphocyte-specific protein (Lck), mitogen activated protein kinase (MAPK), amyloid precursor protein intracellular domain (AICD), α-synuclein and the stem-cell factor receptor (c-kit). Studies have shown the role of imatinib in modulating the pathophysiological state of a number of disorders affecting brain and spinal cord such as Alzheimer’s disease, Parkinson’s disease, stroke, multiple sclerosis and spinal cord injury. The present review discusses the role of imatinib in the above described disorders and the possible mechanisms involved in these diseases.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1043-6618 1096-1186 1096-1186
DOI:	10.1016/j.phrs.2019.03.014